6 9

Cited 0 times in

Cited 0 times in

AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3-4 Pulmonary Nodules: A Multicenter Prospective Cohort Study

Authors
 Lee, Bora  ;  Kim, Chi Young  ;  Eom, Jung Seop  ;  Ji, Wonjun  ;  Kim, Min Jee  ;  Yoon, Sung Hoon  ;  Ahn, June Hong  ;  Lim, Jun Hyeok  ;  Chung, Chaeuk  ;  Park, Dong Won  ;  Lee, Seung Hyeun  ;  Yeo, Chang Dong 
Citation
 BIOMEDICINES, Vol.14(5), 2026-04 
Article Number
 1013 
Journal Title
BIOMEDICINES
Issue Date
2026-04
Keywords
lung cancer ; pulmonary nodules ; biomarker ; aptamer ; disease staging
Abstract
Background: The AptoDetect (TM)-Lung assay is an aptamer-based test designed for risk assessment in patients with pulmonary nodules, but its potential role in predicting lung cancer stage has not been evaluated. We investigated whether the assay could predict advanced-stage disease beyond conventional diagnostic modalities. Methods: This multicenter prospective cohort study enrolled 1672 patients with Lung-RADS 3-4 pulmonary nodules across ten university-affiliated hospitals in South Korea between June 2023 and December 2024. Among them, 934 patients with histologically confirmed lung cancer were retrospectively selected, and 852 patients were included in the final analysis after exclusions. The AptoDetect (TM)-Lung assay was performed before invasive diagnostic procedures. Results: Among the 852 patients, 450 (52.8%) had advanced-stage disease. The AptoDetect (TM)-Lung score was significantly higher in advanced-stage than in early-stage lung cancer (median, 6.2 vs. 2.8, p < 0.001). In a multivariable logistic regression analysis, a high AptoDetect (TM)-Lung score (>= 5) was independently associated with advanced disease (odds ratio 1.99, 95% confidence interval 1.35-2.95, p < 0.001). The AptoDetect (TM)-Lung assay showed moderate discrimination of advanced-stage disease (area under the curve [AUC] 0.696) and in non-small cell lung cancer (AUC 0.720), whereas its discriminative ability was limited in small cell lung cancer (AUC 0.561). A combined prediction model incorporating the AptoDetect (TM)-Lung assay, serum CEA, and radiologic findings demonstrated improved discriminative performance (AUC 0.821). Conclusions: The AptoDetect (TM)-Lung assay score was independently associated with advanced-stage lung cancer and could provide clinically useful information for early risk stratification before definitive diagnosis and staging are available.
Files in This Item:
94455.pdf Download
DOI
10.3390/biomedicines14051013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chi Young(김치영)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/213007
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links